Profilo
Sara Blum Sherman is currently working as Vice President-Investor Relations at Exscientia AI Ltd.
and Exscientia Plc.
She previously worked as Senior Director-Investor Relations & Strategy at DBV Technologies SA from 2016 to 2020 and as Head-Investor Relations at UroGen Pharma Ltd.
Posizioni attive di Sara Blum Sherman
| Società | Posizione | Inizio |
|---|---|---|
| EXSCIENTIA PLC | Contatto Relazioni con gli Investitori | 01/08/2021 |
Exscientia AI Ltd.
 Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Contatto Relazioni con gli Investitori | - |
Precedenti posizioni note di Sara Blum Sherman
| Società | Posizione | Fine |
|---|---|---|
| UROGEN PHARMA LTD. | Contatto Relazioni con gli Investitori | 01/08/2021 |
| DBV TECHNOLOGIES | Public Communications Contact | 01/09/2020 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| DBV TECHNOLOGIES | Health Technology |
| UROGEN PHARMA LTD. | Health Technology |
| EXSCIENTIA PLC | Health Technology |
| Aziende private | 1 |
|---|---|
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Sara Blum Sherman